U.S. markets closed

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.64+0.22 (+4.06%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.42
Bid5.61 x 1800
Ask5.67 x 900
Day's Range5.43 - 5.86
52 Week Range3.12 - 9.00
Avg. Volume1,803,255
Market Cap232.658M
Beta (5Y Monthly)2.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies

    Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies

    Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting. The treatment was associated with improved sleep in children with clinically significant sleep disorders at baseline. Furthermore, the children with both DEE and autism spectrum disorder (ASD) showed m

  • Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside

    Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside

    Clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) has received guidance from the U.S. Food and Drug Administration (FDA) for a Phase 3 trial of Zygel to treat Fragile X syndrome (FXS). FXS is a rare genetic disability that causes inherited intellectual disability as well as autism spectrum disorders. In the Phase 3 trial, called RECONNECT, the efficacy and safety profile of Zygel will be evaluated in children and adolescents with FXS. Zygel, which is a gel that delivers CBD (non-euphoric cannabinoid) through the skin, targets the behavioral effects of FXS. Zynerba Chairman and CEO Armando Anido said, “Following productive discussions and alignment with the FDA, we believe we have a clear path forward for Zygel in Fragile X syndrome. We are excited to advance Zygel into the RECONNECT trial, a pivotal, multi-national, confirmatory Phase 3 trial in patients with FXS in the third quarter of 2021.” (See Zynerba stock analysis on TipRanks) Anido added, “If the results are positive, Zygel could become the first FDA approved treatment option for the significant unmet medical need that affects patients with FXS and their families.” Recently, Roth Capital analyst Scott Henry reiterated a Buy rating on the stock but lowered the price target to $7.25 (66.3% upside potential) from $8. Commenting on Zynerba’s Q4 results as “within expectations,” Henry also noted the sufficient cash available to the company, which will last until 1H 2024. Consensus on the Street is that Zynerba Pharmaceuticals is a Moderate Buy based on 2 Buys and 1 Hold. The average analyst price target of $7.63 implies 75% upside potential. That’s after the stock has seen an approximate 17.5% gain over the past six months. Related News: Where Does Roku Stand Ahead Of Its 1Q Earnings Release? PayPal Earnings Preview: Here’s What To Expect Verizon To Sell Media Business To Apollo Management For $5B But Will Retain 10% Stake More recent articles from Smarter Analyst: Zynga Snaps up Chartboost For $250M Camping World Snaps Up Hilmerson RV; Street Sees 25.5% Upside Apple Expands Its App Store Ads Wix Snaps Up Rise.ai To Drive Long-Term Customer Value

  • Inside the Top-Performing ETFs of Q1

    Inside the Top-Performing ETFs of Q1

    Amplify Seymour Cannabis ETF (CNBS) topped the list of the best-performing ETFs of February with impressive returns of about 60%.